Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?

Current Opinion in Urology

Volumn 21, Issue 5, 2011, Pages 434-439

  Niegisch, Günter ^a   Albers, Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bladder cancer; clinical trial; neoadjuvant chemotherapy; neoadjuvant treatment; prognostic factors; urothelial carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; BLADDER CANCER; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHRONIC KIDNEY FAILURE; CYSTECTOMY; DISEASE COURSE; DISEASE FREE SURVIVAL; GLOMERULUS FILTRATION RATE; HISTOLOGY; HUMAN; HYDRONEPHROSIS; KIDNEY FUNCTION; KIDNEY INJURY; PATIENT SELECTION; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SMALL CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION; TREATMENT RESPONSE;

COMBINED MODALITY THERAPY; CYSTECTOMY; DRUG THERAPY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 80051784638     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328349582e     Document Type: Review

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
2. Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55:815-825.
3. Yafi FA, Aprikian AG, Chin JL, et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 2010; doi: 10.1111/j.1464-410X.2010. 09912.x [Epub ahead of print]. This is a recent retrospective series of more than 2000 bladder cancer patients who underwent radical cystectomy. In contrast to more 'classical' series, also data on patients' performance status and on comorbidities are provided.
4. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 2001;19:666-675. (Pubitemid 32120143)
5. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis. Lancet 2003;361:1927-1934.
6. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171(2 Pt 1):561-569. (Pubitemid 38090430)
7. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) metaanalysis collaboration. Eur Urol 2005;48:202-205; discussion 205-206.
8. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866. (Pubitemid 37025405)
9. Malmstrom PU, Rintala E, Wahlqvist R, et al. Five-year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996;155:1903-1906. (Pubitemid 26144081)
10. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007;52:134-141. (Pubitemid 46803003)
11. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.
12. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638-2646. (Pubitemid 32441368)
13. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12. (Pubitemid 36043346)
14. Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011;117:276-282.
15. Canter D, Viterbo R, Kutikov A, et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 2011;77:160-165. This retrospective analysis demonstrates that treatment decision in cancer patients is not only dependent on type and stage of tumor but also to a larger part on patient's general condition.
16. Hallan SI, Orth SR. The conundrum of chronic kidney disease classification and end-stage renal risk prediction in the elderly: what is the right approach? Nephron Clin Pract 2010;116:c307-c316.
17. International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999;354:533-540.
18. Mayer EK, Bottle A, Darzi AW, et al. The volume-mortality relation for radical cystectomy in England: retrospective analysis of hospital episode statistics. BMJ 2010; doi: 10.1136/bmj.c1128.
19. Mamidanna R, Stonell C, Faiz O. Complications and mortality in older surgical patients in Australia and New Zealand (the REASON study): a multicentre, prospective, observational study. Anaesthesia 2011;66:132-133. This retrospective analysis demonstrates that treatment decision in cancer patients is not only dependent on type and stage of tumor but to a larger part on patient's general condition.
20. Koga F, Kihara K, Fujii Y, et al. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. BJU Int 2009;104:189-194.
21. Hollenbeck BK, Miller DC, Dunn RL, et al. The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urol Oncol 2005;23:77-81. (Pubitemid 40616296)
22. Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011. This work reminds that further efforts in ameliorating pretherapeutic cancer staging are of urgent need.
23. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009;55:761-769.
24. Abou-El-Ghar ME, El-Assmy A, Refaie HF, et al. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology 2009;251:415-421.
25. El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion-and T2-weighted MR imaging. Eur Radiol 2009;19:1575-1581.
26. Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging - accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009;251:112-121.
27. Lehmann J, Suttmann H, Albers P, et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 2009;55:1293-1299.
28. Abe T, Shinohara N, Harabayashi T, et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 2007;52:1106-1113.
29. Sweeney P, Millikan R, Donat M, et al. Is there a therapeutic role for postchemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 2003;169:2113-2117. (Pubitemid 36576729)
30. Siefker-Radtke AO, Walsh GL, Pisters LL, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004;171:145-148. (Pubitemid 37549110)
31. Wasco MJ, Daignault S, Zhang Y, et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007;70:69-74. (Pubitemid 47081105)
32. Scosyrev E, Ely BW, Messing EM, et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 2010. In this posthoc analysis, it was shown that mixed histologies do not affect the response to MVAC neoadjuvant chemotherapy.
33. Kastritis E, Dimopoulos MA, Antoniou N, et al. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res 2006;26:3865-3869. (Pubitemid 44701473)
34. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 2009;3(6 Suppl 4):S193-S198.
35. Cheng L, Pan CX, Yang XJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 2004;101:957-962. (Pubitemid 39100428)
36. Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 2004;172:481-484. (Pubitemid 38900183)
37. Siefker-Radtke AO, Kamat AM, Grossman HB, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009;27:2592-2597.
38. Sanchez-Ortiz RF, Huang WC, Mick R, et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003;169:110-115; discussion 115. (Pubitemid 35461564)
39. Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011;12:137-143. In this study, one of the most promising tools for molecular cancer staging is presented. Lymph-node positive patients were identified by a prediction model based on the expression of 20 genes with appropriate accuracy.
40. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011;22:139-144.
41. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009;69:8302-8309.